COMPASS Study for Metastatic Castration-resistant Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is a companion to the SYNERGY-201 clinical trial (NCT06228053), which investigates SX-682 and enzalutamide in individuals with prostate cancer. Individuals must be participating in SYNERGY-201 in order to participate in this study. The purpose of this companion study is to learn more about biomarkers, particularly a biomarker called CXCR2, and investigate if CXCR2 can predict who will receive benefit from the SYNERGY-201 drug combination. This study will also investigate how CXCR2 and other biomarkers change over time when participants receive the SYNERGY-201 drug combination. CXCR2 is of particular interest because the SYNERGY-201 drug, SX-682, inhibits CXCR2. After participants provide consent, blood samples will be collected for research purposes at three SYNERGY-201 visits (Baseline, Cycle 3 Day 1 and End of Study Drug). Up to 20 participants will also receive tumor biopsies at the Baseline and SYNERGY-201 Cycle 3 Day 1 visits. Clinical and study data collected as part of SYNERGY-201 will also be used for this study.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek powyżej 18 lat
- •Uczestnictwo w badaniu głównym SYNERGY-201
- •Chęć i możliwość podpisania świadomej zgody na uczestnictwo
✗ Disqualifies
- •Przebyte lub obecne schorzenia, leczenie lub wyniki badań, które mogłyby wpłynąć na wiarygodność wyników
- •Warunki, które mogłyby uniemożliwić udział przez całą długość badania
- •Warunki, które w ocenie lekarza byłyby niekorzystne dla pacjenta
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 27, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (4)
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, United States
Rogel Cancer Center
Ann Arbor, United States
Duke University
Durham, United States
University of Wisconsin Carbone Cancer Center
Madison, United States
Trial contact
Kellie Shobe, MS, BSN, RN
Monika Anand, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/28/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.